Drug firm Zydus Cadila has said that it has received final nod from the United States Food and Drug Administration (USFDA) to market generic Desoximetasone cream used for the treatment of various skin conditions.

Cadila said in a statement that the approval from the US FDA is to market Desoximetasone cream USP 0.25 per cent in America, Zydus. The company added that the product will be manufactured at the Zydus Cadila’s topical manufacturing facility at Ahmedabad.

Zydus Cadila said, “Desoximetasone is a strong corticosteroid, used to treat a variety of skin conditions such as eczema, dermatitis, allergies and rash.” It reduces the itching, swelling, and redness that can occur in these types of conditions, the company added.

The group now has 219 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs).

Read EquityPandit’s Nifty Pharma Outlook for the Week